Zydus receives final approval from the USFDA for Darunavir Tablets 600 mg and 800 mg
Darunavir is a protease inhibitor antiviral medicine that prevents Human Immunodeficiency Virus (HIV-1) from multiplying in the body
Darunavir is a protease inhibitor antiviral medicine that prevents Human Immunodeficiency Virus (HIV-1) from multiplying in the body
The Regional Reference Laboratory in Chennai is equipped with cutting-edge diagnostic technologies
Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial
Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment
C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II
The agreement includes an upfront payment of US$15 million, regulatory and commercial milestones, and royalties
The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Almost 300 million people globally have chronic hepatitis B
Subscribe To Our Newsletter & Stay Updated